Foghorn Therapeutics said its Q3 2026 update showed continued progress across its oncology and immunology and inflammation pipeline. Focus areas included an ora

Foghorn Therapeutics said its Q3 2026 update showed continued progress across its oncology and immunology and inflammation pipeline. Focus areas included an oral IBD program, a selective EP300 degrader and a novel induced-proximity approach.